Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?
Related Questions
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?
Would you recommend SBRT in the adjuvant settings for a solitary metastasis focus in the abdominal wall resected to R1 in a young and healthy patient with clear cell ovarian cancer?
What adjuvant therapy would you recommend for a patient with high grade serous ovarian cancer who has surgically confirmed unresectable disease after a partial response to 6 cycles of a platinum doublet?
Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?
What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?
Would you prescribe vaginal estrogen cream for vaginal dryness to a patient in her 40s with a history of stage IA granulosa cell tumor?
How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?